Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Celltrion acquires Eli Lilly's Branchburg plant

PRIVATEAug 13, 2026•about 2 hours ago

Acquiring Company

Celltrion

Acquired Company

Eli Lilly

Incheon

IndianapolisManufacturingBiotechnologyTherapeuticsPharmaceuticalBiopharmaManufacturingBiotechnologyHealth CarePharmaceutical

Description

Celltrion has acquired Eli Lilly's drug substance manufacturing plant in Branchburg, New Jersey for $330 million. This acquisition aims to establish Celltrion's own production capabilities in the U.S. market. The company is actively working to navigate regulatory requirements to commence its own product manufacturing. Celltrion's successful adaptation will be critical in avoiding Novo Nordisk's regulatory pitfalls.

Company Information

Company

Celltrion

Location

Incheon, Seoul, South Korea

About

Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for several products, enhancing its portfolio in the biopharmaceutical industry.

Don't miss Celltrion's next move

Get an email the moment Celltrion makes an acquisition, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Celltrion's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Eli Lilly?

Eli Lilly was acquired by Celltrion, based in Incheon. The deal was reported on August 13, 2026. Celltrion is privately held and operates in Manufacturing.

When did Celltrion acquire Eli Lilly?

Celltrion's acquisition of Eli Lilly was reported on August 13, 2026. Celltrion has acquired Eli Lilly's drug substance manufacturing plant in Branchburg, New Jersey for $330 million. This acquisition aims to establish Celltrion's own production capabilities in the U.S. market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Eli Lilly do?

Eli Lilly is a global healthcare and pharmaceutical company focused on the discovery, development, and delivery of innovative pharmaceutical medicines, vaccines, and consumer healthcare products. It is publicly traded (LLY), operating in Manufacturing, and is based in Indianapolis.